BCG vaccine extensively used even in countries where efficacy against pulmonary tuberculosis is negligible. A number of possible reasons for the variable efficacy of BCG in different countries have been proposed. None have been proven, some have been disproved, and none can explain the lack of efficacy in both low-TB burden countries (US) and high-TB burden countries (India). The reasons for variable efficacy have been discussed at length in a WHO document on BCG. BCG has protective effects against some non-tuberculosis mycobacteria. BCG has been one of the most successful immunotherapies. BCG vaccine has been the "standard of care for patients with
Inoculation theory regarding the impact of gender on inoculation effectiveness in issue/advocacy campaigns. The conclusion was made that females are more likely to be inoculated with these types of campaigns. An additional observation made by Burgoon et. al (1995) was that the type of content used in these campaigns contributed to the campaigns success. The further the advertisement was from "direct self-benefit" the greater the inoculation effect was on the audience (Burgoon, et al., 1995). It took quite some time for inoculation theory to be applied to marketing, because of the many limitations (Lessne and Didow, 1987). Lessne and Didow (1987) reviewed